Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides
Filed with ASX · · 20 pages · English
A replay of the webcast will also be made available at www.immutep.com from the day after the event. Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or cl
In the deck
Story so far
Earlier from Immutep
- Immutep reports supportive efficacy data from AIPAC study
- Immutep receives 2nd IND approval for efti from US FDA
- Immutep reports positive TACTI-002 data
- Immutep Activities Report
- Immutep expands Part C of TACTI-002 due to positive data
Later from Immutep
- EOC Pharma confirms plans to advance Efti in China for MBC
- Immutep presents TACTI-002 data at AACR Virtual Meeting
- Immutep advances its LAG-3 agonist for autoimmune diseases
- Immutep March Quarterly Activities Report & Appendix 4C
- Enrollment completed for the INSIGHT-004 Study
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep